	US 12,233,080 B2
	Lipotechoic acid for immune modulation
Stephen F. Murphy, Chicago, IL (US); Praveen Thumbikat, Chicago, IL (US); and Anthony Schaeffer, Hinsdale, IL (US)
Assigned to Northwestern University, Evanston, IL (US)
Filed by Northwestern University, Evanston, IL (US)
Filed on Sep. 29, 2020, as Appl. No. 17/037,079.
Application 17/037,079 is a continuation of application No. 15/923,679, filed on Mar. 16, 2018, granted, now 10,799,520.
Claims priority of provisional application 62/473,022, filed on Mar. 17, 2017.
Prior Publication US 2021/0023109 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/085 (2006.01); A61K 9/00 (2006.01); A61K 31/7032 (2006.01); A61K 35/00 (2006.01); A61K 35/741 (2015.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01); A61P 37/06 (2006.01)

CPC A61K 31/7032 (2013.01) [A61K 9/0031 (2013.01); A61K 9/0053 (2013.01); A61K 35/741 (2013.01); A61K 39/085 (2013.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); A61P 37/06 (2018.01); A61K 2035/115 (2013.01)]

6 Claims

1. A method of treating an inflammation-related and/or immune-related autoimmune disease or condition in a subject, the method comprising administering to the subject s composition formulated for administration to a subject comprising lipoteichoic acid (LTA) obtained from a non-pain-inducing (NPI) strain of Staphylococcus epidermidis having the deposit number PTA-127829.